Individual Plaintiff Opioid Cases Now Emerging in The Opiate Litigation
Most discussions in the legal community have focused on the “entity” plaintiffs thus far and these entity cases certainly have merit however, our researchers believe the largest number of potential plaintiffs with viable cases against the opioid manufacturers are those claims related to individual plaintiff injuries and deaths.
Learn More About the Opioid Individual Case Emerging Litigation
The Opioid Individual Case Emerging Litigation will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at email@example.com or call (954) 520-4494.
For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”
Your PI Firm Has Already Represented Individuals Who May Now Have Viable Opioid Cases
Given the fact that the first opioid prescription a person ever receives often occur due to an auto accident, a work related injury or another injury which results in the filing of a personal injury case, your firm has already represented numerous individuals who now have claims related to opioids. Sign these individual plaintiffs you already have before someone else does
Unlike the entity cases which as a general rule name a host of manufacurers as well as distributors as defendants, some individual opioid cases may be brought against a single manufacturer while others may be filed based on legal theories that will require naming some or all of the alleged “opioid conspirators”.
The “individual case” opioid litigation will be different than a typical mass tort litigation involving a pharmaceutical product. Different claims will exist against different manufacturers and arise from different causes.
The single most important first step for any law firm considering accepting clients with individual opioid cases will be to learn how to properly qualify clients.
Examples of Opioid Claims Arising from FDA Actions
Opana ER: June 2017 U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks.
Codeine and Tramadol Can Cause Breathing Problems for Children
FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women issued on April 20, 2017.
These medicines can cause life-threatening breathing problems in children. Some children and adults break down codeine and tramadol into their active forms faster than other people. That can cause the level of opioids in these people to rise too high and too quickly.
January 2018 FDA Drug Safety Communication: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older
The U.S. Food and Drug Administration (FDA) is requiring safety labeling changes for prescription cough and cold medicines containing codeine or hydrocodone to limit the use of these products to adults 18 years and older because the risks of these medicines outweigh their benefits in children younger than 18.
The Individual Opioid cases (arising from a given cause) listed above are only a fraction of the universe of these types of opioid cases. Attend the May Four Days to Mass Tort Success Course for a broader coverage of the individual case opioid litigation.
Mass Tort Nexus is also hosting a national “Opioid Crisis Summit” July 21-22, 2018 here in Fort Lauderdale
This event will be unlike ANY other opioid conference ever presented to attorneys. CNN, Associated Press, STAT NEWS (The Boston Globe), The Sun-Sentinel, ABC and NBC will be here to cover this event because never before has such a comprehensive group of experts been assembled to explain how the Opioid Crisis began and how it has affected our country. Leading politicians, medical doctors, treatments centers, academics and attorneys will come together to tell the story of what happened from their vast experience in dealing with this crisis, for more than two decades.
WHY DO YOU NEED TO ATTEND THIS EVENT?
Contrary to popular belief, it is not too late to acquire entity cases (state, county, city, union, private insurers, etc.) There are an estimated 10,000 entity cases and less than 1% have been signed. Mass Tort Nexus has the data for every county in the country, along with an index score to arm you with the information to write accurate complaints and customize them in great detail.
The universe of individual cases will potentially be in excess of one million plaintiffs. Over 90 million Americans were prescribed opioids in the last year alone and there is not one segment of society that has not been affected. The only litigation that compares to it in size and scope is the tobacco litigation; however, there is one big difference – the opioid litigation is likely to resolve far more quickly. We will reveal the reasons why. Our keynote speakers include Ohio Lt. Governor Mary Taylor and Dr. Rahul Gupta, Director of Public Health, State of West Virginia and others with real time, day to day experience in dealing with opioid crisis as well as providing solutions.
For complete information on this major Opioid Summit and the nationally prominent guest speakers – follow the link below: